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ABSTRACT 
Drug resistance is one of the major challenges facing the success of chemotherapy against human hepatocarcinoma 
(HCC) as well as other types of cancer. Studies with cell lines can serve as initial screening for agents that could modu-
late drug resistance. Development of a good experimental model of drug-resistant cells is a prerequisite for the success 
of such cellular studies; but could be laborious and generally time-consuming. Additionally, the high mortality rate as-
sociated with advanced HCC calls for a probe into the mechanism of resistance by developing experimental model that 
mimics clinical method of its treatment. Consequently, we have reported a simplified method of selection of drug-re-
sistant hepatocarcinoma cells from human hepatocellular carcinoma (HEPG2) cell line using pharmacologic agents, 
cisplatin (CDDP) and 5-fluorouracil (5-FU). HEPG2 cell line was incubated for 24 hours with different concentrations 
of CDDP (0 - 20 µM) or 5-FU (0 - 100 µM). Cell viability was assayed by CCK-8 (Cell Counting Kit) analysis, and the 
inhibitory concentrations (IC50) for CDDP and 5-FU were established by dose-dependent cytotoxicity curves. The 
IC50(s) were confirmed by flow cytometric analysis of cell death due to CDDP or 5-FU. Clinical method of treatment 
was imitated by treating the parental HEPG2 cell line in pulse, at the optimal concentration of either CDDP or 5-FU for 
4 to 6 hours. Induction was repeated 6 times, whilst allowing the cells to attain at least 70% confluence between inter-
vals of induction. The resultant drug-resistant sub-lines, (HEPG2CR) and (HEPG2FR) were found to be stable after 
over 3 months of drug withdrawal and maintenance in drug-free medium. This was done with the views of establishing 
a simple, efficient and direct protocol for the development of good cellular models for the study of drug resistance in 
liver cancer, with possible application in other cancer types. 
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1. Introduction 
Primary liver cancer is the fifth most common cancer world- 
wide and the third most deadly, accounting for approxi- 
mately 600,000 deaths annually. Hepatocellular carcinoma 
(HCC), a primary malignancy of the hepatocyte, accounts 
for 85% to 90% of all primary liver cancer; out of which 
80% of HCC cases occur in either sub-Saharan Africa or 
eastern Asia [1,2]. The continuous increase in HCC pre- 
valence and high mortality rate as indicated by average 
survival rate of less than 12 months for patients diag-
nosed with advanced HCC, are reflectors of lack of effec- 
tive therapy [3]. 
Cisplatin (CDDP) and 5-fluourouracil (5-FU) are two 
different and frequently used anticancer drugs with wide 
range of anti-tumour activities. CDDP has been used as a 
chemotherapeutic agent in many cancers, especially in tes-
ticular cancer and epidermal carcinomas of many organs, 
for which treatment is very successful [4]. 5-FU, a 
pyrimidine antimetabolite, is one of the first-line treat- 
ment options for gastrointestinal tumours and represents 
the most widely used chemotherapeutic agent in the ma- 
nagement of hepatocarcinoma [5]. Treatment of human 
hepatocellular carcinoma with cisplatin has shown more 
effectiveness than any other anti-neoplastic agents; and 
when combined with 5-FU, cisplatin has been shown to 
induce additive and synergistic results [6,7]. For patients 
with advanced HCC, intra-arterial combination chemothe- 
rapy is one of the few successful options, and continuous 
use of CDDP and 5-FU has been shown to prolong the 
survival of such patients [8]. 
Many resistant tumour cells in humans are gradually 
acquired during chemotherapeutic administration. Drug- 
resistant cell lines, selected by exposure to anticancer 
agents could serve as valuable tools for the illumination 
of factors underlying drug resistance [9]. The develop- 
ment of good experimental model of drug resistant cell 
line is a vital prerequisite for any study to understand the 
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mechanisms of drug resistance. Until now, though, models 
for development of drug-resistant cell lines in various 
cell types have been reported. However, such models have 
either used the method of increasing continuous admini-
stration [10] or low-dosage intermittent incremental in-
ducement [11]. These methods are associated with various 
and inconsistent dosages, without recourse to clinical me- 
thod of chemotherapeutic administration from which can- 
cer cells acquire resistance. 
In the present study, we established CDDP-resistant 
and 5-FU-resistant cell lines from parental HEPG2 cell 
line by imitating the clinical pattern of chemotherapy, the 
pulse treatment. This was done following the establish- 
ment of the optimal concentrations of CDDP and 5-FU at 
which 50% cell death is achieved (the inhibitory concen- 
tration, IC50). In the end, highly stable, drug-resistant 
sub-lines of HEPG2 cell line were produced, and a simple 
protocol that adopts clinical method was established. This 
protocol would serve as a useful guide to researchers in-
tending to produce drug-resistant cell line, especially for 
the study of drug resistance in HCC and other forms of 
liver cancer. 
2. Materials and Methods 
2.1. Pharmacologic Agents 
5-fluorouracil (5-FU) and cisplatin (CDDP) (Sigma Al- 
drich, UK) were dissolved in double distilled water to 
yield working stocks at concentration of 20 mM and 2 mM 
respectively. The working stocks were stored at room tem- 
perature. 
2.2. Cell Line and Culture Conditions 
The parental human hepatocellular carcinoma (HEPG2) 
cell line was obtained from the European Collection of 
Animal Cell Cultures (ECACC). Cells were cryopreserved 
and then rapidly thawed and grown in RPMI 1640 me-
dium (Invitrogen, UK), fully supplemented with 10% heat- 
inactivated foetal bovine serum (FBS) (Invitrogen, UK), 
1% glutamine (Invitrogen, UK) and 1% penicillin strep-
tomycin (Invitrogen, UK). The physiological conditions 
of the cells were maintained at 5% CO2 and 37˚C in a hu- 
midified atmosphere. Logarithmically growing cells were 
at the second passage when they were cryopreserved with 
a freezing medium containing 10% dimethylsulphoxide 
(DMSO) (Sigma Aldrich, UK) and 90% supplemented 
RPMI 1640 medium (Invitrogen, UK). The freezing vials 
containing the cells were cryo-preserved in a cryovial 
containing isopropanol and maintained at –80˚C for 24 
hours; and the vials containing the parental cells were 
finally maintained as working stock at –196˚C in liquid 
nitrogen. 
2.3. Cell Viability Assay 
Cell viabilities in response to chemotherapeutic induction, 
and the degrees of cytotoxicity of CDDP and 5-FU on 
the cells were measured using cell counting kit (CCK-8) 
(Sigma Aldrich, UK). The CCK-8 is made up of Do-
jindo’s highly water-soluble tetrazolium salt, WST-8[2- 
(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disul
fophenyl)-2H-tetrazolium, monosodium salt]; which pro- 
duces a water-soluble, yellowish formazan dye upon re- 
duction in an electron carrier [12]. The number of viable 
cells is directly proportional to the amount of the forma- 
zan dye generated in cells. Assays were done following 
manufacturer’s instruction. Briefly, cells were seeded at 
density of 104 cells per well in 96-well plates and pre- 
incubated overnight for adherence at physiological con- 
ditions of 5% CO2 and 37˚C, in a humidified atmosphere. 
The cells were then treated at concentrations of 0 µM to 
20 µM for CDDP; and 0 µM to 100 µM for 5-FU. After 
12 to 24 hours incubation, 10 µl of CCK-8 was added to 
each well and incubated at 37˚C for 2 hours; followed by 
the measurement of absorbance using an automated mi- 
cro-plate reader ELx 800 (BioTek, UK) at 450 nm. Each 
experiment was done in triplicates and the results were 
the mean of at least three independent measurements and 
expressed as percentage of the absorbance of untreated 
control cells ± S.E.M. 
2.4. Determination of Inhibitory Concentrations 
The inhibitory concentration otherwise known as IC50, is 
the optimal concentration at which the survival rate of 
HEPG2 cells reached the minimum following exposure 
to an appropriate anticancer drug [13]. Determination of 
this concentration (IC50) is primordial to the selection of 
cells for any drug resistance. Briefly, cells at the loga- 
rithmic growth phase (80% confluence) were harvested 
and seeded at a density of 104 cells per well in 96-well 
plates and incubated overnight for proper adherence. Sub- 
sequently, the drug-free medium was replaced with pre- 
warmed fully supplemented fresh medium, containing 0 
µM to 100 µM of 5-FU or 0 µM to 20 µM of CDDP. The 
cells were incubated for 24 hours, while maintaining the 
physiological conditions at 5% CO2 and 37˚C tempera-
ture, in a humidified atmosphere. After 24 hours incuba-
tion, cell viability assessment was conducted colorimet-
rically using cell counting kit-8 (CCK-8) (Sigma Aldrich, 
UK). The optical densities (OD) of cells treated at dif-
ferent drug concentrations were measured at 450 nm us-
ing a micro-plate reader ELx 800 (BioTek, UK); and cell 
viability was calculated as a measure of the optical den-
sity (OD) of treated cells relative to the optical density of 
the untreated controls, excluding the OD of blank con-
trols. Dose-dependent response curve was plotted and the 
respective inhibitory concentrations (IC50) of CDDP and 
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5-FU were established. 
2.5. Flow Cytometric Analysis of Cell Death 
The inhibitory concentrations (IC50) were confirmed by 
the flow cytometric analysis of cell death using Annexin 
V-FITC kit (BD Biosciences, San Diego). Briefly, HE- 
PG2 cells were grown to 80% confluence, and detached 
using 0.25% (w/v) trypsin in 5 mM EDTA (Invitrogen). 
The cells were seeded at the rate of 2 × 105 per ml of 
RPMI 1640 medium (Invitrogen), supplemented with 
10% foetal bovine serum (Invitrogen), 1% Penicillin stre- 
ptomycin (Invitrogen), and 1% L-glutamine (Invitrogen). 
After 24 hour incubation in appropriate concentrations of 
CDDP (0 - 16 µM) or 5-FU (0 - 90 µM), under physio- 
logical conditions of 5% CO2, 37˚C, in a humidified at- 
mosphere; the cells were detached by trypsinization, washed 
and re-suspended in binding buffer. The cells were ana-
lysed for apoptosis following mixing with Annexin V- 
FITC and propidium iodide (PI), and incubation in the 
dark for 5 minutes. Analysis was done using flow cy-
tometer FACSCalibur (BD Biosciences, Europe). 
2.6. Selection of Cells for Resistance 
In selection of the cells for resistance, clinical method of 
treatment was adopted. The parental HEPG2 cell line 
was treated in pulse, at the IC50 of either CDDP or 5-FU 
for 4 to 6 hours. Induction was repeated 6 times, whilst 
allowing the cells to attain at least 70% confluence be- 
tween induction intervals. After 6 complete cycles of 
induction, selected cells were maintained in drug-free 
RPMI 1640 medium containing appropriate supplements, 
and passaged at the attainment of 70% - 80% confluence. 
No further experiment was performed on the cells until 
after 4 weeks maintenance in drug-free medium, whilst 
testing the stability of the developed resistance. 
2.7. Test for Resistance 
The stabilities of the selected clones (HEPG2CR) and 
(HEPG2FR) were tested after 2 weeks, one month and 3 
months of drug withdrawal. Briefly, the selected clones 
were harvested at exponential growth phase using 0.25% 
trypsin-EDTA. Cell counting was performed using hea- 
matocytometer, and the cells were seeded in 96-well 
plate at the rate of 104 cells per well, in triplicates. Plates 
were maintained at 37˚C in a humidified atmosphere of 
5% CO2. After overnight incubation for attachment, cells 
were incubated for 24 hours in RPMI 1640 medium con- 
taining appropriate concentration of CDDP (0 - 20 µM) 
or 5-FU (0 - 100 µM). Following the 24 hours incubation, 
the cells were further incubated for 2 hours in the pre- 
sence of 10 µl of CCK-8 per well. The optical densities 
were measured and the new IC50 was obtained from a 
dose-dependent cytotoxicity curve for each of the drugs 
as previously described. The difference between the IC50 
of the resistant clone and that of the parental cell line 
defines the degree of resistance. 
3. Results 
3.1. Pharmacological Induction of Cell Death 
and Measurement of Cell Viability 
To understand the effect of CDDP or 5-FU on HEPG2 
cell viability and establish the degree of cytotoxicity due 
to these drugs, HEPG2 cell line was incubated for 24 
hours with 0 µM to 20 µM of CDDP or 0 µM to 100 µM 
of 5-FU. Cell viabilities were measured by CCK-8 assay 
and HEPG2 cell line was found to be more susceptible to 
CDDP than 5-FU. Furthermore, with 5-FU, cytotoxicity 
was found to be directly proportional to dose and time. 
However, for CDDP, an approximately reciprocal degree 
of cytotoxicity was obtainable at both 12 hours treatment 
and 24 hours treatment with similar concentration (Fig-
ure 1). 
3.2. Establishment and Confirmation of 
Inhibitory Concentrations (IC50) 
To determine the concentration of CDDP or 5-FU be- 
yond which HEPG2 cell survival was minimum, the cells 
were exposed to different concentrations of CDDP (0 µM 
to 20 µM) or 5-FU (0 µM to 100 µM) for 24 hours. The 
respective inhibitory concentration was calculated from a 
dose-dependent response curve, following analysis of 
cell viability by CCK-8 assay. For CDDP, cell survival 
was minimal beyond 4 µM (Figure 1), but in the case of 
5-FU, cell survival was minimal beyond 50 µM (Figure 
2). Hence, the IC50 of CDDP was found to be 4 µM while 
that of 5-FU was 50 µM. The inhibitory concentrations 
were confirmed by the flow cytometric analyses of cell 
deaths due to CDDP or 5-FU (data not shown). 
3.3. Development of Drug Resistant Sublines and 
Test for Resistance 
Following the establishment of the concentration of 
CDDP or 5-FU at which HEPG2 cell viability is reduced 
by 50%, the resistant sublines HEPG2CR and HEPG2FR 
were established by incubating the parental HEPG2 cell 
line at the IC50 of CDDP (4 µM) or 5-FU (50 µM, whilst 
imitating the clinical method of treatment. The cells were 
found to have developed resistance to either CDDP or 
5-FU following six intervals of induction. A test for re- 
sistance was conducted after 2 weeks of growth in drug- 
free medium, and a comparison of the IC50 of the paren-
tal cells and those of the resistant cells revealed a re-
markable increase. For CDDP, the IC50 of HEPG2CR 
was double that of the parental cell line, hence a 100% 
increase (Figure 3). However, for 5-FU, the IC50 of 
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Comparison of HEPG2 Cell Viability at 12 and 24 Hours CDDP 
Treatment 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
0 2 4 6 8 10 12 14 16 18 20
C
el
l V
ia
bi
lit
y 
(%
) 
12 hours treatment 
24 hours treatment
CDDP Concentration (μM)  
Figure 1. CCK-8 assay of viability of HEPG2 cell line in 
response to CDDP at different intervals. 
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Figure 2. CCK-8 assay of HEPG2 cell viability following 
5-FU treatment. 
 
 Relative viabilities of HEPG2 and the CDDP-resistant subclone, HEPG2CR
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Figure 3. A comparison of the IC50 of parental HEPG2 cell 
line and that of the resistant subline (HEPG2CR). 
 
HEPG2FR was found to be 65 µM as against the 50 µM 
of the parental cell line (Figure 4). 
4. Discussion 
Many resistant tumour cells in humans are gradually ac- 
quired during chemotherapy. Drug-resistant cell line mo- 
dels serve as useful paradigms for the clinical scenario of 
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Figure 4. Relative IC50(s) of HEPG2 cell line and the 5- 
FU-resistant clone, HEPG2FR. 
 
anticancer drug resistance. Cell line models with acquired 
resistance to a variety of anticancer agents have been vari- 
ously developed in the quest to unravel the mechanisms 
underlying clinical drug resistance [13-15]. 
Primary liver cancers, especially HCC, are associated 
with very low survival rate and high mortality rate, occa- 
sioned by a high degree of resistance to chemotherapy. It 
is therefore, vitally important to carry out studies targeted 
to understanding the factors underlying the clinical drug 
resistance abilities of liver cancers. Such studies require 
good models of drug-resistant cell lines that are reflective 
of clinical drug resistance scenario for the cancer type 
under investigation. Consequently, we have reported herein, 
a simple, stepwise protocol for the establishment of drug- 
resistant models of liver cancer, whilst imitating the cli- 
nical method of treatment. The human hepatocellular 
carcinoma (HEPG2) cell line was used as a model in the 
presence of anticancer agents, CDDP and 5-FU. 
The protocol primarily involves choice and establish- 
ment of parental cell line, assessment of sensitivity of 
parental cell line to drugs against which resistance is to 
be developed, establishment of the IC50 dose, selection of 
resistant cells, and test for resistance and stability. 
The first step during the development of drug-resistant 
cell line is the choice of parental cell line. This is subject 
to a number of factors, such as tumour type and its rele-
vance to the selecting agents under consideration [16]. 
The human hepatocellular carcinoma (HEPG2) cell line 
was chosen because it is the most prevalent [1,2] and 
deadliest [3] form of liver cancer. In relation to the selec-
tion agents, CDDP and 5-FU combination therapy is the 
most sensitive and preferred treatment option for patients 
with advanced HCC patients [8]. 
Following the choice of parental cell line, it is impor- 
tant to establish the degree of sensitivity of the cell line 
to the drugs in question. Such drug sensitivity assay is a 
prerequisite to the identification of the initial dose of 
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treatment [16]. The sensitivity of parental HEPG2 cell 
line to CDDP or 5-FU was tested by measuring its viabil- 
ity using the cell counting kit-8. The results of the assays 
revealed that HEPG2 cell line is more sensitive to CDDP 
than 5-FU. The inhibitory concentration for CDDP or 
5-FU was calculated as 4 µM or 50 µM respectively, 
from dose-dependent cytotoxicity curves. 
On establishing the appropriate concentrations of CDDP 
and 5-FU at which the resistant sub-lines of HEPG2 cell 
line could be produced, the resistant cell lines were then 
established at these concentrations as described in the 
method section. The selection process mimicked the cli- 
nical method of treatment, as the parental cell line was 
treated in pulse, whilst allowing the cells to recover be-
tween treatment intervals. The resistant cell lines, HE- 
PG2CR and HEPG2FR, were maintained in drug-free 
medium after complete selection. After the sixth induc-
tion, an increase in the IC50 for both drugs was an indica-
tion of resistance development. The IC50 of CDDP-re-
sistant HEPG2 cell line doubled that of the parental cell 
line, whereas, that of 5-FU-resistnat cell line increased 
by a shorter margin relative to that of the parental cell 
line. This shows that HEPG2 cell line has stronger cyto-
toxicity memory for 5-FU; hence, the faster development 
of resistance to 5-FU relative to CDDP. The stability of 
the resistant cell lines was tested and they were found to 
be very stable in drug-free medium, as indicated by con-
stant IC50 after months of maintenance in drug-free me-
dium. This is against some reports that drug-resistant cell 
lines needed to grow in drug-containing medium in order 
to retain the stability of drug resistance [17]. Hence, our 
research provides the basis for the establishment of highly 
stable drug-resistant cell line, with minimal cost of pro-
duction and maintenance. 
In conclusion, development of good experimental mod-
els of drug-resistant cells is indispensable to the success of 
cellular and molecular studies of drug resistance mecha-
nisms. The high mortality rate associated with advanced 
HCC calls for a probe into its mechanism of resistance to 
chemotherapy. Consequently, the protocol reported here- 
in, could serve as a simplified method of selection of drug- 
resistant hepatocellular carcinoma cells from human he- 
patocellular carcinoma (HEPG2) cell line using pharma-
cologic agents and assuming clinical treatment pattern. 
The stepwise method of selection as outlined, could serve 
as a firsthand guide for the selection of drug-resistant cell 
line needed for any liver cancer-related drug-resistance 
studies. 
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